Microbiology

back

References

  • 1. Silley P et al. Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats. Journal of Antimicrobial Chemotherapy 2007; 60: 999-1003.
  • 2. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with focus on five new ‘respiratory quinolones’. Journal of Antimicrobial Chemotherapy 1999; 43 (B): 1-11.
  • 3. Walker RD. and Dowling PM. In: Guagere S. et al. Antimicrobial Therapy in Veterinary Medicine, 2006; 4th edition. Blackwell Publishing: 264.
  • 4. Hawkey PM. Mechanisms of quinolone action and microbial response. Journal of Antimicrobial Chemotherapy (2003); 51(1): 29-35.
  • 5. Dowers KL et al. Use of a novel fluoroquinolone to treat experimentally-induced Mycoplasma haemofelis in cats. Am J Vet Res (2009); 70: 105-111.
  • 6. Hartmann AD et al. Efficacy of Pradofloxacin in Cats with Feline Upper Respiratory Tract Disease due to Chlamydophila felis or Mycoplasma Infections. J Vet Intern Med (2008); 22: 44-52.
  • 7. Biswas S et al. Comparative Activity of Pradofloxacin, Enrofloxacin, and Azithromycin against Bartonella henselae Isolates Collected from Cats and a Human. Journal of Clinical Microbiology 2010: 617-618.
  • 8. Pridmore A et al. In vitro activity of pradofloxacin against clinical isolates from European field studies. American Society for Microbiology (ASM) 105th General Meeting 2005, Atlanta, USA. Abstract Z-033.
  • 9. Doerner JC et al. Pradofloxacin: in vitro activity against various canine and feline bacterial pathogens in four EU countries. 4th Symposium on Antimicrobial Resistance in Animals and the Environment (ARAE) 2011, Tours, France. P23.
  • 10. Abraham J et al. Pradofloxacin: comparative in vitro activity against selected pathogens from the US. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2002, California, USA. Abstract F-568.
  • 11. De Jong A and Bleckmann I. Comparative activity of pradofloxacin against clinical canine and feline strains from Germany. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (2003), Chicago, USA. Abstract F-419.
  • 12. De Jong A et al. Antibacterial activity of pradofloxacin against canine and feline pathogens isolated from clinical cases. 2nd International conference on Antimicrobial Agents in Veterinary Medicine (AAVM) 2004, Ottawa, USA.
  • 13. Bayer internal study report - data on file.
  • 14. Bayer internal study report - data on file.
  • 15. Bayer internal study report - data on file.
  • 16. Bayer internal study report - data on file.
  • 17. Bayer internal study report - data on file.
  • 18. Bayer internal study report - data on file.
  • 19. Bayer internal study report - data on file.
  • 20. Bayer internal study report - data on file.
  • 21. Bayer internal study report - data on file.
  • 22. Bayer internal study report - data on file.
  • 23. Bayer internal study report - data on file.
  • 24. Bayer internal study report - data on file.
  • 25. Bayer internal study report - data on file.
  • 26. Bayer internal study report - data on file.
  • 27. Bayer internal study report - data on file.
  • 28. Bayer internal study report - data on file.
  • 29. Stephan B et al. Activity of Pradofloxacin against Porphyromonas and Prevotella spp. implicated in Periodontal Disease in Dogs: Susceptibility Test Data from a European Multicenter Study. Antimicrobial agents and chemotherapy 2008; X: 2149-2155.
  • 30. Silley P et al. Bactericidal properties of pradofloxacin against veterinary pathogens. Veterinary Microbiology 2012; 157: 106-111.
  • 31. Dong Y et al. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:  1756-1758.
  • 32. Blondeau JM et al. The role of PK ⁄ PD parameters to avoid selection and increase of resistance: mutant prevention concentration. J Chemotherapy 2004; 16: 1-19.
  • 33. Wetzstein HG. Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance. Antimicrob Agents Chemother 2005; 4166-4173.
  • 34. Ball P et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002; 49: 31-40.
  • 35. Tillotson GS et al. Fluoroquinolones as pneumococcal therapy: closing the barn door before the horse escapes. Lancet Infect Dis 2001; 1: 145-146.
  • 36. Thomson KS. Minimizing quinolone resistance: are the new agents more or less likely to cause resistance? J Antimicrob Chemother 2000; 45: 719-723.
Rate this page

latest documents

3rd row with links